Reversion of hepatic stellate cell to a quiescent phenotype: From myth to reality?
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
COMMENTARY ON: Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B, Tsukamoto H, Evans SM, Dillmann W, Glass CK, Brenner DA. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9448-53. Copyright (2012). Abstract reprinted by permission from the National Academy of Sciences, USA. http://www.ncbi.nlm.nih.gov/pubmed/22566629Abstract: Myofibroblasts produce the fibrous scar in hepatic fibrosis. In the carbon tetrachloride (CCl(4)) model of liver fibrosis, quiescent hepatic stellate cells (HSC) are activated to become myofibroblasts. When the underlying etiological agent is removed, clinical and experimental fibrosis undergoes a remarkable regression with complete disappearance of these myofibroblasts. Although some myofibroblasts apoptose, it is unknown whether other myofibroblasts may revert to an inactive phenotype during regression of fibrosis. We elucidated the fate of HSCs/myofibroblasts during recovery from CCl(4)- and alcohol-induced liver fibrosis using Cre-LoxP-based genetic labeling of myofibroblasts. Here we demonstrate that half of the myofibroblasts escape apoptosis during regression of liver fibrosis, down-regulate fibrogenic genes, and acquire a phenotype similar to, but distinct from, quiescent HSCs in their ability to more rapidly reactivate into myofibroblasts in response to fibrogenic stimuli and strongly contribute to liver fibrosis. Inactivation of HSCs was associated with up-regulation of the anti-apoptotic genes Hspa1a/b, which participate in the survival of HSCs in culture and in vivo. AND Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Troeger JS, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC, Pradere JP, Friedman RA, Schwabe RF. Gastroenterology. 2012 Oct;143(4):1073-83.e22. Copyright © 2012. Abstract reprinted by permission from the AGA Institute. http://www.ncbi.nlm.nih.gov/pubmed/22750464Abstract: Background & Aims: Activated hepatic stellate cells (HSCs), the main fibrogenic cell type in the liver, undergo apoptosis after cessation of liver injury, which contributes to resolution of fibrosis. In this study, we investigated whether HSC deactivation constitutes an additional mechanism of liver fibrosis resolution. Methods: HSC activation and deactivation were investigated by single-cell PCR and genetic tracking in transgenic mice that expressed a tamoxifen-inducible CreER under control of the endogenous vimentin promoter (Vimentin-CreER). Results: Single-cell quantitative polymerase chain reaction demonstrated activation of almost the entire HSC population in fibrotic livers, and a gradual decrease of HSC activation during fibrosis resolution, indicating deactivation of HSCs. Vimentin-CreER marked activated HSCs, demonstrated by a 6- to 16-fold induction of a membrane-bound green fluorescent protein (mGFP) Cre-reporter after injection of carbon tetrachloride, in liver and isolated HSCs, and a shift in localization of mGFP-marked HSCs from peri-sinusoidal to fibrotic septa. Tracking of mGFP-positive HSCs revealed the persistence of 40%-45% of mGFP expression in livers and isolated HSCs 30-45 days after carbon tetrachloride was no longer administered, despite normalization of fibrogenesis parameters; these findings confirm reversal of HSC activation. After fibrosis resolution, mGFP expression was observed again in desmin-positive peri-sinusoidal HSCs; no mGFP expression was detected in hepatocytes or cholangiocytes, excluding mesenchymal-epithelial transition. Notably, reverted HSCs remained in a primed state, with higher levels of responsiveness to fibrogenic stimuli. Conclusions: In mice, reversal of HSC activation contributes to termination of fibrogenesis during fibrosis resolution, but results in higher responsiveness of reverted HSCs to recurring fibrogenic stimulation. Activation of hepatic stellate cells (HSC) in response to chronic liver injury is a key step in the pathogenesis of liver fibrosis. The activation process is characterized by a phenotypic switch from a quiescent vitamin A-rich to a myofibroblastic fibrogenic phenotype [[1]Lotersztajn S. Julien B. Teixeira-Clerc F. Grenard P. Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets.Ann Rev Pharmacol Toxicol. 2005; 45: 605-628Crossref PubMed Scopus (284) Google Scholar] (Fig. 1). Fibrosis has long been viewed as an irreversible process, but convincing clinical and experimental studies have demonstrated that fibrosis resolution may occur upon eradication of the liver insult [[2]Ellis E.L. Mann D.A. Clinical evidence for the regression of liver fibrosis.J Hepatol. 2012; 56: 1171-1180Abstract Full Text Full Text PDF PubMed Scopus (340) Google Scholar]. Experimental models of fibrosis recovery consistently reported that elimination of activated HSC by apoptosis [[3]Iredale J. Benyon R. Pickering J. McCullen M. Northrop M. Pawley S. et al.Mechanisms of sponta
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075 · cited 2×
“The low rate of apoptosis compared to previous studies [3] might be due to the ephemeral nature of apoptosis, but nevertheless, these findings argue for the reversion of a significant number of myofibroblastic HSC to a quiescent state during the recovery phase.”
BackgroundResultMyofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
Deactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice
Troeger, J. S., Mederacke, I., Gwak, G., Dapito, D. H., Mu, X., Hsu, C. C., Pradere, J., Friedman, R. A., & Schwabe, R. F. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.036 · Cited by 515
Clinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411 · cited 1×
“Fibrosis has long been viewed as an irreversible process, but convincing clinical and experimental studies have demonstrated that fibrosis resolution may occur upon eradication of the liver insult [2].”
BackgroundXie, G., Wang, X., Wang, L., Wang, L., Atkinson, R. D., Kanel, G. C., Gaarde, W. A., & DeLeve, L. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.017 · Cited by 410 · cited 1×
“In addition, the role of neighboring cells also warrants further investigation, in particular the liver sinusoidal endothelial cells, which control HSC activation/deactivation [9].”
BackgroundHepatic stellate cells require a stiff environment for myofibroblastic differentiation
Olsen, A. L., Bloomer, S. A., Chan, E. P., Gaça, M. D. A., Georges, P. C., Sackey, B., Uemura, M., Janmey, P. A., & Wells, R. G. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00412.2010 · Cited by 355
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Self-citation
Cited by
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets
Zhang, C.-Y., Yuan, W.-G., He, P., Lei, J.-H., & Wang, C.-X. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i48.10512 · Cited by 594
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis
Mallat, A., & Lotersztajn, S. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00230.2013 · Cited by 211
“Recent cell tracking studies have further documented earlier in vitro studies showing that activated HSCs can undergo deactivation to a quiescent phenotype following cessation of liver injury (41, 54, 89).”
BackgroundSelf-citationThe role of mouse strain differences in the susceptibility to fibrosis: a systematic review
Walkin, L., Herrick, S. E., Summers, A., Brenchley, P. E., Hoff, C. M., Korstanje, R., & Margetts, P. J. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-18 · Cited by 160
“When injury occurs, a heterogenous population of hepatic myofibroblasts are primarily responsible for the fibrotic response [66].”
BackgroundZhao, W., Yuan, W., Dong, T., Qi, W., Feng, Z., Li, C., & Sun, Y. (2025) · Communications Biology · doi:10.1038/s42003-025-08160-2 · Cited by 16
Metadata
- Authors
- Mallat, A., & Lotersztajn, S.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 59
- Issue
- 2
- Pages
- 383-386
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2020973322
- Cited by
- 30
- References
- 8
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reversion of hepatic stellate cell to a quiescent phenotype: From myth to reality? https://app.cochat.ai/papers/10.1016/j.jhep.2013.03.031
- The paper
- Mallat, A., & Lotersztajn, S. (2013). Reversion of hepatic stellate cell to a quiescent phenotype: From myth to reality? Journal of Hepatology. https://doi.org/10.1016/j.jhep.2013.03.031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.